Biogen’s tau therapy drives bigger benefits in 2-year Alzheimer’s update

BIOGEN3.jpg?VersionId=mcuq5OM0MuI.g67GpT2l967eEtp5_H5Q

Biogen has linked its tau-targeting antisense oligonucleotide to a further slowing of clinical decline after two years, leading analysts to hail the strengthening of evidence supporting late-phase development.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks